CIK 0001400118 · <br>Emerging growth company
Sagimet Biosciences Inc.
Sign in to watch- Ticker
- SGMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205991472
- Phone
- (650) 561-8600
- Business address
- 950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
- Former names
- 3-V Biosciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −526,332 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +526,332 | 526,332 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −21,173 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +21,173 | 21,173 | ||
| 2023-07-18 | Hom Dennis Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −111,438 | 0 | ||
| 2023-07-18 | Hom Dennis Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +111,438 | 111,438 | ||
| 2023-07-18 | Hom Dennis Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −9,286 | 0 | ||
| 2023-07-18 | Hom Dennis Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +9,286 | 9,286 | ||
| 2023-07-18 | Hom Dennis Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −136,846 | 0 | ||
| 2023-07-18 | Hom Dennis Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +136,846 | 136,846 | ||
| 2023-07-18 | Happel David President & CEO | Returned to the company · Stock Option (Right to Buy) | −1,011,826 | 0 | ||
| 2023-07-18 | Happel David President & CEO | Grant or award · Stock Option (Right to Buy) | +1,011,826 | 1,011,826 | ||
| 2023-07-18 | GRAMMER ELIZABETH A Director | Returned to the company · Stock Option (Right to Buy) | −49,533 | 0 | ||
| 2023-07-18 | GRAMMER ELIZABETH A Director | Grant or award · Stock Option (Right to Buy) | +49,533 | 49,533 |
Page 10 of 10 · 194 trades